Search

Your search keyword '"Cyclobenzaprine"' showing total 25 results
Start Over Descriptor "Cyclobenzaprine" Journal globenewswire
25 results on '"Cyclobenzaprine"'

1. Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia, the Prototypic Nociplastic Pain Syndrome, at the IASP 2024 World Congress on Pain

Subjects
United States. Food and Drug Administration, Fibromyalgia -- Drug therapy, Cyclobenzaprine, Banking, finance and accounting industries, Business
Abstract

Bedtime TNX-102 SL (sublingual cyclobenzaprine HCl) treatment in the Phase 3 RESILIENT study resulted in statistically significant improvement in the primary endpoint of fibromyalgia nociplastic pain and in all six [...]

Published
2024

2. Tonix Pharmaceuticals Presented Poster of Tonmya(TM) for the Management of Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2024

Subjects
United States. Food and Drug Administration -- Management, Fibromyalgia, Cyclobenzaprine, Company business management, Banking, finance and accounting industries, Business
Abstract

Treatment with Tonmya(TM) (TNX-102 SL, sublingual cyclobenzaprine HCl) in Phase 3 RESILIENT study significantly reduced daily pain and demonstrated broad fibromyalgia symptom improvement, as demonstrated by significant improvement on the [...]

Published
2024

3. Tonix Pharmaceuticals Announces Two Poster Presentations of TNX-102 SL (Sublingual Cyclobenzaprine HCl) at the ASCP Annual Meeting

Subjects
United States. Food and Drug Administration, Fibromyalgia, Central nervous system depressants, Cyclobenzaprine, Traffic accidents, Banking, finance and accounting industries, Business
Abstract

In the Phase 2 PREVAIL trial in fibromyalgia-type Long COVID, bedtime TNX-102 SL resulted in a signal in fatigue, sleep and cognitive function Phase 2, investigator-initiated OASIS trial is designed [...]

Published
2024

4. Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring

Subjects
United States. Food and Drug Administration, Fibromyalgia, Cyclobenzaprine, Banking, finance and accounting industries, Business
Abstract

Tonix recently reported results from second positive Phase 3 trial of Tonmya(TM) for the management of fibromyalgia In the U.S., New Drug Application (NDA) submission to the FDA planned for [...]

Published
2024

5. Tonix Pharmaceuticals Announces Research Indicating Pre-Existing Fibromyalgia-Type Symptoms May Increase the Risk of Developing Long COVID

Subjects
United States. Food and Drug Administration, Medical research, Medicine, Experimental, Fibromyalgia, Medical records, Cyclobenzaprine, Banking, finance and accounting industries, Business
Abstract

Retrospective observational study of electronic medical records of more than 90 million people living in the U.S. Long COVID shares symptoms with chronic overlapping pain disorders like fibromyalgia and appears [...]

Published
2024

6. Tonix Pharmaceuticals Completes Enrollment in Potentially NDA-Enabling Phase 3 RESILIENT Trial of TNX-102 SL for Management of Fibromyalgia

Subjects
United States. Food and Drug Administration -- Management, Fibromyalgia, Cyclobenzaprine, Company business management, Banking, finance and accounting industries, Business, Tosymra (Medication)
Abstract

Topline Data Expected Fourth Quarter 2023 Final Trial Required for Submission of a New Drug Application, if Successful CHATHAM, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. [...]

Published
2023

7. Tonix Pharmaceuticals Initiates Enrollment in the RESILIENT Study, a Potentially Pivotal Phase 3 Study of TNX-102 SL for the Management of Fibromyalgia

Subjects
Fibromyalgia, Cyclobenzaprine, Company business management, Banking, finance and accounting industries, Business
Abstract

CHATHAM, Apr 07, 2022 (GLOBE NEWSWIRE via COMTEX) -- Results from Planned Interim Analysis Expected First Quarter 2023 A Positive Outcome in RESILIENT Together with Results from Previous Positive Phase [...]

Published
2022

9. Tonix Pharmaceuticals Enrolls First Patient in Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia

Subjects
United States. Food and Drug Administration -- Management, Medical research, Fibromyalgia, Cyclobenzaprine, Company business management, Banking, finance and accounting industries, Business
Abstract

NEW YORK, Dec 10, 2019 (GLOBE NEWSWIRE via COMTEX) -- Interim Analysis Results Expected Second Half 2020 Topline Results Expected First Half 2021 Based on the Currently-Planned Sample Size Tonix [...]

Published
2019

10. Tonix Pharmaceuticals Announces Initiation of the Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia

Subjects
United States. Food and Drug Administration -- Management, Fibromyalgia, Cyclobenzaprine, Stock offerings, Company business management, Banking, finance and accounting industries, Business
Abstract

NEW YORK, Nov 21, 2019 (GLOBE NEWSWIRE via COMTEX) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that, having successfully closed [...]

Published
2019

11. Tonix Pharmaceuticals Announces 12-Week Primary Endpoint and Addition of Adaptive Design Features in the Currently-Enrolling Phase 3 RECOVERY Study of Tonmya(R) for PTSD, Following FDA Meeting

Subjects
United States. Food and Drug Administration, Post-traumatic stress disorder -- Care and treatment, Cyclobenzaprine, Banking, finance and accounting industries, Business
Abstract

NEW YORK, Nov 04, 2019 (GLOBE NEWSWIRE via COMTEX) -- Primary Endpoint Will be Mean Change from Baseline in CAPS-5 at Week 12, Instead of Week 4 Results from Added [...]

Published
2019

12. Tonix Pharmaceuticals Announces that the European Patent Office Opposition Division Has Upheld Its Patent for the Use of the Active Ingredient in TNX-102 SL, Cyclobenzaprine, for the Treatment of PTSD

Subjects
Central nervous system depressants -- Intellectual property, Post-traumatic stress disorder, Cyclobenzaprine, Banking, finance and accounting industries, Business
Abstract

NEW YORK, Oct 07, 2019 (GLOBE NEWSWIRE via COMTEX) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the European Patent [...]

Published
2019

13. Tonix Pharmaceuticals Announces that Breakthrough Therapy Designation Remains in Effect for Tonmya(R) for the Treatment of Posttraumatic Stress Disorder

Subjects
United States. Food and Drug Administration, Biological products, Cyclobenzaprine, Post-traumatic stress disorder, Backup software, Pain management, Biological weapons, Pharmaceutical industry, Bioterrorism, Banking, finance and accounting industries, Business
Abstract

NEW YORK, April 22, Apr 22, 2019 (GLOBE NEWSWIRE via COMTEX) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company developing pharmaceutical products to [...]

Published
2019

14. Tonix Pharmaceuticals Provides Update on Tonmya(R) for the Treatment of Posttraumatic Stress Disorder

Subjects
United States. Food and Drug Administration, Biological products, Cyclobenzaprine, Post-traumatic stress disorder -- Care and treatment, Backup software, Biological weapons, Pharmaceutical industry, Bioterrorism, Banking, finance and accounting industries, Business
Abstract

NEW YORK, March 01, Mar 01, 2019 (GLOBE NEWSWIRE via COMTEX) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company focused on developing pharmaceutical [...]

Published
2019

15. Tonix Pharmaceuticals to Present at Noble Capital Markets' Fourteenth Annual Investor Conference in Fort Lauderdale

Subjects
United States. Food and Drug Administration, Cyclobenzaprine, Post-traumatic stress disorder, Banking, finance and accounting industries, Business
Abstract

NEW YORK, Jan 24, 2018 (GLOBE NEWSWIRE via COMTEX) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), announced today that it will present at Noble Capital Markets' Fourteenth Annual Investor Conference [...]

Published
2018

16. Tonix Pharmaceuticals to Present at 10th Annual LD Micro Investor Conference

Subjects
United States. Food and Drug Administration, Cyclobenzaprine, Biological products, Post-traumatic stress disorder, Banking, finance and accounting industries, Business
Abstract

NEW YORK, Nov 30, 2017 (GLOBE NEWSWIRE via COMTEX) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company in Phase 3 development of Tonmya(R)* (cyclobenzaprine HCI sublingual tablets), or TNX-102 [...]

Published
2017

17. Tonix Pharmaceuticals Reports Outcomes from U.S. FDA Breakthrough Therapy CMC Guidance Meeting of Tonmya(R) (Cyclobenzaprine HCI Sublingual Tablets) for PTSD

Subjects
United States. Food and Drug Administration, Central nervous system depressants, Cyclobenzaprine, Biological products, Post-traumatic stress disorder -- Care and treatment, Banking, finance and accounting industries, Business
Abstract

NEW YORK, Oct 17, 2017 (GLOBE NEWSWIRE via COMTEX) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical and biological products to address public health [...]

Published
2017

18. Tonix Pharmaceuticals to Present at the Dawson James Securities 3rd Annual Small Cap Growth Conference

Subjects
United States. Food and Drug Administration, Conferences and conventions, Cyclobenzaprine, Biological products, Post-traumatic stress disorder, Banking, finance and accounting industries, Business
Abstract

NEW YORK, Oct 12, 2017 (GLOBE NEWSWIRE via COMTEX) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company developing innovative pharmaceutical and biological products to address major public health challenges, [...]

Published
2017

19. Tonix Pharmaceuticals to Present at the Rodman & Renshaw 19th Annual Global Investment Conference

Subjects
United States. Food and Drug Administration, Rodman & Renshaw L.L.C., Conferences and conventions, Investment banks, Cyclobenzaprine, Biological products, Post-traumatic stress disorder, Banking, finance and accounting industries, Business
Abstract

NEW YORK, Sep 06, 2017 (GLOBE NEWSWIRE via COMTEX) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company developing innovative pharmaceutical and biological products to address major public health challenges, [...]

Published
2017

20. Tonix Pharmaceuticals Participated in the 'Pathophysiology of Posttraumatic Stress Disorder: Rethinking Drug Targets' Summit Sponsored by U.S. Department of Defense

Subjects
United States. Department of Defense, United States. Food and Drug Administration, Cyclobenzaprine, Post-traumatic stress disorder -- Drug therapy, Banking, finance and accounting industries, Business
Abstract

NEW YORK, June 15, Jun 15, 2017 (GLOBE NEWSWIRE via COMTEX) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to address public health [...]

Published
2017

21. Tonix Pharmaceuticals Presented Retrospective Analyses of Treatment Response and Remission to TNX-102 SL in a Phase 2 Military-Related PTSD Study

Subjects
United States. Food and Drug Administration, Cyclobenzaprine, Post-traumatic stress disorder, Banking, finance and accounting industries, Business
Abstract

NEW YORK, May 30, May 30, 2017 (GLOBE NEWSWIRE via COMTEX) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to address public health [...]

Published
2017

22. Tonix Pharmaceuticals to Present Clinical Data at CNS Summit 2016

Subjects
United States. Food and Drug Administration, Cyclobenzaprine, Post-traumatic stress disorder, Banking, finance and accounting industries, Business
Abstract

NEW YORK, Oct 27, 2016 (GLOBE NEWSWIRE via COMTEX) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing a next-generation treatment for posttraumatic stress disorder (PTSD), announced today that [...]

Published
2016

23. Tonix Pharmaceuticals Presents at EULAR Results of a Retrospective Analysis from the Phase 2b BESTFIT Clinical Study of TNX-102 SL in Fibromyalgia

Subjects
Clinical trials, Fibromyalgia, Cyclobenzaprine, Post-traumatic stress disorder, Banking, finance and accounting industries, Business
Abstract

NEW YORK, June 09, Jun 09, 2016 (GLOBE NEWSWIRE via COMTEX) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia (FM) and post-traumatic stress disorder [...]

Published
2016

24. Tonix Pharmaceuticals Presents Pharmacokinetic Data on TNX-102 SL as a Potential Treatment for the Management of Fibromyalgia and Treatment of Post-Traumatic Stress Disorder at the ASCPT 2016 Annual Meeting

Subjects
Fibromyalgia -- Drug therapy, Cyclobenzaprine, Post-traumatic stress disorder -- Drug therapy, Banking, finance and accounting industries, Business
Abstract

NEW YORK, March 09, Mar 09, 2016 (GLOBE NEWSWIRE via COMTEX) -- - TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for bedtime administration currently under development for the [...]

Published
2016

25. Tonix Pharmaceuticals and U.S. Department of Defense Military Developer in Partnership to Expand Efforts to Examine TNX-102 SL for Post-Traumatic Stress Disorder

Subjects
Cyclobenzaprine, Post-traumatic stress disorder, Banking, finance and accounting industries, Business
Abstract

NEW YORK, Dec 07, 2015 (GLOBE NEWSWIRE via COMTEX) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ('Tonix'), which is developing next-generation medicines for fibromyalgia, post-traumatic stress disorder (PTSD), and episodic tension-type [...]

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results